logo
  • Home
  • About Us
  • Cognition
  • Pipeline
  • News
  • Talent
  • Contact
中
  • Industry Trends
  • Technological Frontier
  • Information of YuanVore
Location: Home > News > Industry Trends
  • Experts recommend autologous stem cells as a third type of medical technology management
    01
    2024-11
    2024-11-01
    Our country should also follow international practice and promote "autologous stem cells as a third type of medical technology management."
  • Case! Stem cell treatment for diabetes is safe and effective, and getting rid of insulin may be achieved!
    14
    2024-10
    2024-10-14
    In the cutting-edge exploration of diabetes treatment, stem cell therapy is showing unprecedented potential and prospects.
  • Bioprocess technology of induced pluripotent stem cells (iPSC)
    11
    2024-10
    2024-10-11
    This article provides an overview of cell culture media, suspension models, and monitoring technologies that can maintain the quality and pluripotency of iPSC during induction, expansion, and production.
  • 6000 clinical trials around the world, stem cells may trigger a medical revolution
    10
    2024-10
    2024-10-10
    With the continuous development of technology, stem cells will surely trigger a medical revolution and become the third treatment method after drugs and surgery.
  • Stem cell drugs: the next generation of pharmaceutical products, a new revolution in disease treatment
    30
    2024-09
    2024-09-30
    As a new pharmaceutical product, stem cell drugs are expected to make huge contributions to the pharmaceutical and medical industries in the near future.
  • iPS cell-derived mesenchymal stem cells have powerful immunoregulatory and regenerative properties
    29
    2024-09
    2024-09-29
    New research demonstrates the great promise of iMSCs and iMSCs-EVs as alternative sources of MSC-derived therapies because of their powerful immunomodulatory and regenerative properties.
  • Nearly 100 clinical INDs of stem cell drugs have been approved in my country! In 2024, my country will add 20 new stem cell products, 17 of which are mesenchymal stem cells
    27
    2024-09
    2024-09-27
    From January 1 to September 30, 2024, a total of 20 items were approved to acquiesce in clinical trials (implied approval for clinical trials), of which 17 items were derived from mesenchymal stem cells.
  • INDs approved for 9 domestic CGT therapies (September 2024)
    24
    2024-09
    2024-09-24
    As a new frontier of medicine, cell and gene therapy is showing great potential and development momentum. Especially in the treatment of refractory diseases, more and more clinical trials of cell and gene therapy are being opened.
Prev
... 4 5 6 7 8 ...
Next
logo

Phone:021-64051958

Email:info@yuanvore.com

  • Cognition
    Cognition
    CellBank
    Platform
    Patent
  • Pipeline
    PipelineLayout
  • News
    Industry Trends
    Technological Frontier
    Information of YuanVore
  • Talent
    Enterprise Culture
    Job Information
  • About Us
    Contact Us
CopyRight @ 2023 Shanghai Yuanvore Medicine Technology Co., Ltd. AIl Rights Reserved 沪ICP备2023021701号

沪公网安备31011202020042号